BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 48,316 shares of the stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $312.25, for a total value of $15,086,671.00. Following the sale, the chief executive officer owned 9,180 shares of the company's stock, valued at $2,866,455. This represents a 84.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
John Oyler also recently made the following trade(s):
- On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The stock was sold at an average price of $317.67, for a total value of $19,503,984.99.
- On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The shares were sold at an average price of $298.34, for a total value of $3,489,981.32.
- On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The shares were sold at an average price of $304.35, for a total value of $14,767,062.00.
- On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total value of $44,626,172.95.
- On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The stock was sold at an average price of $273.78, for a total transaction of $933,589.80.
- On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
- On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The shares were sold at an average price of $257.24, for a total transaction of $501,360.76.
- On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total transaction of $1,336,566.40.
BeOne Medicines Trading Up 1.4%
Shares of ONC opened at $330.46 on Wednesday. The stock has a market capitalization of $36.26 billion, a P/E ratio of 73.93 and a beta of 0.49. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The firm has a fifty day simple moving average of $292.77 and a two-hundred day simple moving average of $309.37. BeOne Medicines Ltd. - Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22.
BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a net margin of 8.94% and a return on equity of 12.06%. The firm had revenue of $1.51 billion for the quarter. On average, research analysts anticipate that BeOne Medicines Ltd. - Sponsored ADR will post 5.93 EPS for the current year.
Institutional Trading of BeOne Medicines
Several large investors have recently bought and sold shares of ONC. EFG International AG purchased a new position in shares of BeOne Medicines during the 4th quarter worth approximately $25,000. Leonteq Securities AG bought a new position in shares of BeOne Medicines in the 4th quarter worth approximately $35,000. Daiwa Securities Group Inc. purchased a new position in shares of BeOne Medicines in the 2nd quarter valued at approximately $35,000. CWM LLC lifted its stake in shares of BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company's stock valued at $48,000 after purchasing an additional 39 shares during the period. Finally, Group One Trading LLC bought a new stake in shares of BeOne Medicines during the fourth quarter valued at approximately $61,000. 48.55% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on ONC shares. Guggenheim boosted their price target on BeOne Medicines from $410.00 to $420.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Zacks Research cut BeOne Medicines from a "strong-buy" rating to a "hold" rating in a report on Friday, July 3rd. Nomura upgraded BeOne Medicines to a "strong-buy" rating in a research report on Monday. Truist Financial boosted their target price on BeOne Medicines from $413.00 to $416.00 and gave the company a "buy" rating in a research note on Tuesday, July 7th. Finally, Leerink Partners boosted their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an "outperform" rating in a research note on Friday, May 15th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, BeOne Medicines currently has an average rating of "Moderate Buy" and a consensus target price of $394.00.
Read Our Latest Report on BeOne Medicines
About BeOne Medicines
(
Get Free Report)
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
